Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$9.07
-1.4%
$11.54
$7.80
$28.09
$494.90MN/A598,206 shs248,783 shs
Immunome, Inc. stock logo
IMNM
Immunome
$8.71
+0.9%
$8.66
$5.15
$16.81
$757.86M1.92888,176 shs441,626 shs
Replimune Group, Inc. stock logo
REPL
Replimune Group
$9.45
-1.0%
$9.05
$6.44
$17.00
$728.50M0.61864,055 shs581,094 shs
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$3.28
+2.5%
$3.22
$2.65
$9.55
$181.52M0.85479,521 shs303,242 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
0.00%+4.18%-21.10%-4.58%+907,399,900.00%
Immunome, Inc. stock logo
IMNM
Immunome
0.00%-0.68%-4.60%+48.13%-27.60%
Replimune Group, Inc. stock logo
REPL
Replimune Group
0.00%+1.29%-8.96%+26.17%+16.52%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
0.00%+10.81%-7.34%+7.19%-56.38%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Immunome, Inc. stock logo
IMNM
Immunome
2.4347 of 5 stars
3.52.00.00.02.62.50.0
Replimune Group, Inc. stock logo
REPL
Replimune Group
4.1801 of 5 stars
3.61.00.04.52.42.50.6
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3.8118 of 5 stars
3.61.00.04.61.90.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3.00
Buy$31.86251.10% Upside
Immunome, Inc. stock logo
IMNM
Immunome
3.00
Buy$23.33167.89% Upside
Replimune Group, Inc. stock logo
REPL
Replimune Group
3.13
Buy$20.83120.46% Upside
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3.13
Buy$13.39308.23% Upside

Current Analyst Ratings Breakdown

Latest VYGR, IMNM, BCAX, and REPL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
6/20/2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
6/2/2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$14.00 ➝ $22.00
5/23/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$8.00
5/23/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$30.00
5/16/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$44.00 ➝ $41.00
5/13/2025
Immunome, Inc. stock logo
IMNM
Immunome
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$33.00 ➝ $21.00
4/17/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageUnderweight$8.00
4/8/2025
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
4/7/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$45.00 ➝ $44.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/A$9.04 per shareN/A
Immunome, Inc. stock logo
IMNM
Immunome
$9.04M83.83N/AN/A$2.27 per share3.84
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/A$5.40 per shareN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$80M2.27N/AN/A$5.49 per share0.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$68MN/A0.00N/AN/AN/AN/AN/A8/12/2025 (Estimated)
Immunome, Inc. stock logo
IMNM
Immunome
-$292.96M-$3.18N/AN/AN/A-1,875.21%-71.65%-60.36%8/11/2025 (Estimated)
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$247.30M-$3.07N/AN/AN/AN/A-57.98%-45.21%8/14/2025 (Estimated)
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$65M-$1.46N/AN/AN/A-126.49%-27.36%-21.06%8/5/2025 (Estimated)

Latest VYGR, IMNM, BCAX, and REPL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/22/2025Q4 2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$0.75-$0.82-$0.07-$0.82N/AN/A
5/13/2025Q1 2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$0.40-$0.68-$0.28-$0.68N/AN/A
5/12/2025Q1 2025
Immunome, Inc. stock logo
IMNM
Immunome
-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million
5/6/2025Q1 2025
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/AN/A
Immunome, Inc. stock logo
IMNM
Immunome
N/AN/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/AN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
24.62
24.62
Immunome, Inc. stock logo
IMNM
Immunome
N/A
10.49
10.49
Replimune Group, Inc. stock logo
REPL
Replimune Group
0.17
7.95
7.95
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/A
6.10
6.10

Institutional Ownership

CompanyInstitutional Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
Immunome, Inc. stock logo
IMNM
Immunome
44.58%
Replimune Group, Inc. stock logo
REPL
Replimune Group
92.53%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
48.03%

Insider Ownership

CompanyInsider Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
Immunome, Inc. stock logo
IMNM
Immunome
8.60%
Replimune Group, Inc. stock logo
REPL
Replimune Group
8.80%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
4.53%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3254.54 millionN/AN/A
Immunome, Inc. stock logo
IMNM
Immunome
4087.01 million79.53 millionOptionable
Replimune Group, Inc. stock logo
REPL
Replimune Group
21077.09 million70.30 millionOptionable
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
10055.34 million52.83 millionOptionable

Recent News About These Companies

Atlas Announces New Canadian Arctic Expedition Aboard World Voyager
VYGR Voyager Therapeutics, Inc. - Seeking Alpha
Voyager Technologies Soars with IPO Success
Voyager Technologies Shares Soar In Market Debut
Voyager raises $383 million from upsized IPO
Voyager Announces Pricing of Initial Public Offering

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bicara Therapeutics stock logo

Bicara Therapeutics NASDAQ:BCAX

$9.07 -0.13 (-1.37%)
Closing price 07/3/2025 01:34 PM Eastern
Extended Trading
$9.00 -0.07 (-0.80%)
As of 08:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Immunome stock logo

Immunome NASDAQ:IMNM

$8.71 +0.08 (+0.93%)
Closing price 07/3/2025 03:23 PM Eastern
Extended Trading
$8.74 +0.02 (+0.29%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Replimune Group stock logo

Replimune Group NASDAQ:REPL

$9.45 -0.10 (-1.05%)
Closing price 07/3/2025 03:03 PM Eastern
Extended Trading
$9.70 +0.25 (+2.65%)
As of 08:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Voyager Therapeutics stock logo

Voyager Therapeutics NASDAQ:VYGR

$3.28 +0.08 (+2.50%)
Closing price 07/3/2025 03:33 PM Eastern
Extended Trading
$3.24 -0.04 (-1.37%)
As of 08:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.